News and Announcements

Young Investigator Symposium abstracts due Tuesday, September 4, 2018, review eligibility here

Results of TAILORx released, read press release here

Results of NCI-MATCH (EAY131) Arms I, Q, and W released, read press release here

Webinar on patient-reported outcomes research by David Cella, PhD, here

Video that explains the E2112 research study, for men and women with advanced breast cancer, here

New Trials in 2018

July 9, 2018

Now open to patient enrollment: Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer

EA8171 trial info here

May 17, 2018

Now open to patient enrollment: Financial Burden Assessment in Patients with Stage I-III Colon or Rectal Cancer Undergoing Treatment

EAQ162CD trial info here

May 2, 2018

Now open to patient enrollment: Cisplatin / Carboplatin and Etoposide with or without Nivolumab in Treating Patients with Extensive Stage Lung Cancer

EA5161 trial info here

April 26, 2018

Now open to patient enrollment: Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

EA9152 trial info here

April 13, 2018

Now open to patient enrollment: Nivolumab after Combined Modality Therapy in Treating Patients with High Risk Stage II-IIIB Anal Cancer

EA2165 trial info here

April 5, 2018

Now open to patient enrollment: Osimertinib in Treating Patients with Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

EA5162 trial info here

March 28, 2018

Now open to patient enrollment: Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

EA3163 trial info here

March 1, 2018

Now open to patient enrollment: Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer

EA5152 trial info here

February 14, 2018

Now open to patient enrollment: Computed Tomography Perfusion Imaging in Predicting Outcomes in Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Receiving Bevacizumab and Paclitaxel

EAE161 trial info here

February 8, 2018

Now open to patient enrollment: Abiraterone Acetate and Antiandrogen Therapy with or without Cabazitaxel and Prednisone in Treating Patients with Metastatic, Hormone-Sensitive Prostate Cancer Previously Treated with Docetaxel

EA8153 (CHAARTED2) trial info here

Welcome

Welcome to the ECOG-ACRIN Cancer Research Group website, the source of information about the cooperative group that was formed by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN). We are excited to share news of our collaborative effort to design and conduct ground-breaking translational and clinical research.

The merger brought together the strengths and capabilities of two highly respected organizations. Since 1955, ECOG has performed practice-changing multicenter cancer clinical trials, working with more than 6000 physicians, nurses, pharmacists, statisticians, clinical research associates, and cancer research advocates from the United States and around the world. ACRIN, the premier imaging science program in the nation, complements ECOG’s research efforts with its expertise in early detection, imaging diagnosis, comparative-effectiveness research, and cost-effectiveness analysis. Now, as a single entity, we aim to achieve earlier cancer detection, more successful therapeutic intervention, higher rates of prevention, and better patient outcomes.

We look forward to sharing our research and partnering with you, as we reshape the future of patient care.

Robert L. Comis, MD
Group Co-Chair

Mitchell D. Schnall, MD, PhD
Group Co-Chair